This is not the document you are looking for? Use the search form below to find more!

Report home > Others

Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting

0.00 (0 votes)
Document Description
Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting
File Details
Submitter
  • Name: holly

We are unable to create an online viewer for this document. Please download the document instead.

Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting screenshot

Add New Comment




Related Documents

The American Society Of Bariatric Plastic Surgeons Website Expands

by: patrick1gall, 2 pages

(1888PressRelease) The American Society of Plastic Surgeons website now features more information for bariatric patients seeking to reconstruct their face and bodies after excess weight loss as a ...

The American Society of Nephrology (ASN) www.asn-online.org ...

by: seijun, 3 pages

The American Society of Nephrology (ASN) www.asn-online.org ...

Yayoi Kusama on Exhibit at the Whitney Museum of American Art

by: gloriagarfinkel, 3 pages

Celebrated since the 1940s, Japanese artist Yayoi Kusama’s work is included in a career-long retrospective at the Whitney Museum of American Art in New York City.

Web Dogma at the Bauhaus School of Design

by: facunda, 112 pages

Web Dogma at the Bauhaus School of Design

Revelation: Major Paintings by Jules Olitski at the Toledo Museum of Art

by: gloriagarfinkel, 3 pages

Highlighting 30 works from his entire career, the Jules Olitski exhibition at the Toledo Museum of Art showcases Olitski’s transformation through his five major exploratory periods: Stain, ...

Mobile, Social Health at the National Library of Medicine

by: khulood, 2687 pages

Generations Online and the Social Life of Health Information A presentation prepared by Susannah Fox for the National Library of Medicine ...

ETHICAL PRINCIPLES OF THE INTERNATIONAL SOCIETY OF SPORT PSYCHOLGY

by: shinta, 4 pages

“Sport Psychology” is a term used to refer to the psychological aspects of sport, physical recreation, physical education, exercise, health, and related physical activities. The ...

The American Dream and The American Reality of the Jazz Age

by: tero, 39 pages

Because some Georgia high school curricula, including that of Rockdale County Public Schools, mandate a chronological approach to the teaching of American literature, teachers often have to use the ...

Warren Friss Returns as Guest Speaker at the Olin School of Business at Washington University in St. Louis

by: patrick1gall, 2 pages

(1888PressRelease) Warren Friss received a B.S in Political Science from the State University of New York at Albany and then went on to earn a Law Degree from the University of Pennsylvania School of ...

Conceptual Framework of a Principle-based Approach for Life Insurance Products from the American Academy of Actuaries' Universal Life Work Group

by: andrea, 43 pages

This document establishes a conceptual framework for a standard for the valuation of reserves for life insurance policies under a principle-based approach (Approach) as defined below for the products ...

Content Preview
ASCO 2008Analyst BriefingJune 2, 2008Forward-Looking Statements and Non-GAAP Financial Information• Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.• Also, discussions during this meeting may include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measurescan be found in Pfizer’s Current Reports on Form 8-K dated April 17, 2008. • These reports are available on our website at www.pfizer.com in the “Investors—SEC Filings” section.2Pfizer’s Emerging Leadership in OncologyAlison AyersWorld Wide Commercial LeaderPfizer Oncology Leadership TeamGarry NicholsonSeniSeni or Vice or Vice PrePre ss ident/General Mident/General M aa nagernagerAlison AyersCharles BaumCraig EaglePat AndrewsWW CommeWW Comme rrcc ial ial WW DeveloWW Develo pp mentmentWW MedWW Med iical Leadercal LeaderUS GeneraUS Genera l Managerl ManagerLeaderLeaderLeaderLeaderPfizer Regional Pfizer Regional Commercial OperatioCommercial Operatio nsnsMedical OperationsMedical Operations4Pfizer Therapeutic Area PrioritiesInvest to WinFirst or High Market High Best in ClassGrowthUnmet Need• Oncology• Pain• Immunology/Inflammation• Diabetes/Obesity• Alzheimer’s Disease• Schizophrenia 5Oncology R&D AchievementsIncrease in number of oncology R&D projects in past five years400%Ongoing or planned oncology studies 232Oncology compounds in clinical development 22Research budget dedicated to oncology22%6Pfizer’s Four Oncology Research PlatformsANTI-ANGIOGENESISIMMUNOTHERAPYBlocks growth of Reawakens immune tumor blood vesselssystemSIGNAL CYTOTOXIC/TRANSDUCTION POTENTIATORSINHIBITORSExploit defects Blocks cancer in repair and growth signalscycle cells7Advances in the Oncology Pipeline in the ClinicNumber of Compounds in Phase IPhase IIPhase IIIeach PhaseASCO 20081363ASCO 20079448Pfizer Oncology Clinical PortfolioTSP-1(CVX-045)*Platform KeyAng-2 AntAnti-Angiogenesis(CVX-060)*Transitions SinceASCO 2007Signal TransductionALK1 mAb(PF-3446962)ImmunotherapysVEGFR(PF-337,210)Cytotoxic/mRTKPotentiatorsP-Cad mAb(SU-14,813)(PF-3, 732,010)FAKPan-ErbBSutent®(PF-562,271)(PF-00299804)Sutent®C-MetEGFRvlll(PF-2,341,066)(CDX-110)Aromasin®AxitinibC-Met BUTremelimumab(AG-013,736)(PF-4217903)(CP-675,206)Camptosar®IGF-1R mAbHsp90TLR9(CP-751,871)(SNX 5422)(PF-3,512,676)Ellence ®CD40 mAbPARP*Pfizer Biotherapeutics and Bioinnovation Center(CP-870,893)AG-14,699CDK 4/6(PD-332991)CHK1(PF-477,736)AUR2(PF-3,814,73513634Phase IPhase IIPhase IIIApprovedRecent Oncology Licensing and AcquisitionsCompany/CompoundValue to Pfizer PortfolioAvant – licenseNovel vaccine in Phase IIb/III for GBM CDX-110 (EGFRvIII vaccine) High unmet medical needSerenex – acquisitionPhase I, novel mechanismSNX-5422 (Hsp90 inhibitor)Complementary to portfolioCovX – acquisition Two Phase I agents CVX 045 (thrombospondin), Novel anti-angiogenesis mechanisms CVX 060 (angiopoietin)Coley – acquisitionExpands vaccine development capabilityVaccine platform, TLR-7 and TLR-9 programsStrengthens immuno-oncology portfolio10

Download
Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting

 

 

Your download will begin in a moment.
If it doesn't, click here to try again.

Share Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting to:

Insert your wordpress URL:

example:

http://myblog.wordpress.com/
or
http://myblog.com/

Share Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting as:

From:

To:

Share Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting.

Enter two words as shown below. If you cannot read the words, click the refresh icon.

loading

Share Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting as:

Copy html code above and paste to your web page.

loading